Institute for OneWorld Health CEO Outlines Mutually Beneficial Collaborations Between Industry, Nonprofits at BIO.Business Editors/Health/Medical Writers BIO 2004 Annual Convention Booth #5006, Moscone North SAN FRANCISCO--(BUSINESS WIRE)--June 7, 2004 The economics and traditional structure of drug development are shifting in ways that could lead to viable markets for new, affordable drugs in the developing world if biopharmaceutical companies considered innovative collaborations with nonprofits, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Victoria Hale Dr. Victoria Hale founded The Institute for OneWorld Health in San Francisco, California in 2000. Dr. Hale earned her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco (UCSF). , Ph.D., founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of the Institute for OneWorld Health The Institute for OneWorld Health is a 501(c)(3) nonprofit pharmaceutical company founded in 2000 to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing countries. , the first nonprofit pharmaceutical company in the U.S. Dr. Hale will speak at the BIO 2004 Annual International Convention in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden as part of the Global Health track in a panel session titled "Mutually Inclusive: New and Affordable Drugs for Developed, Developing Worlds." The session will take place today, June 7, at 2:15 pm in the Moscone Convention Center, Room #2007 West. Dr. Hale will speak about her company's proven record of collaboration that enables drug companies to partner without compromising their profitability goals. "The benefits of such collaborations are vast," stated Dr. Hale. "By working with us and other like-minded nonprofits, industry is an active partner in bringing new, affordable drugs to cure infectious diseases infectious diseases: see communicable diseases. in the developing world, and helps to nurture new markets." New advances in biotechnology manufacturing, splitting of intellectual property between partners to cover various geographies and indications, donations of promising but unused intellectual property, and sharing investments and risks in drug development are some of the strategies OneWorld Health uses to create collaborations with industry. The most vital resource needed to achieve successful collaborations is people -- professionals with biopharmaceutical expertise. Dr. Hale said OneWorld Health will seek out companies that offer executive loan or sabbatical sab·bat·i·cal also sab·bat·ic adj. 1. Relating to a sabbatical year. 2. Sabbatical also Sabbatic Relating or appropriate to the Sabbath as the day of rest. n. A sabbatical year. programs that would allow their employees to lend their talents to the nonprofit pharmaceutical company in specific programs. The panel consists of: Chair: Tom Brewer Brewer was selected to play in the 1956 Major League Baseball All-Star Game. , Senior Project Officer, Bill & Melinda Gates Melinda French Gates (born Melinda Ann French on August 15, 1964) is a former unit manager for several Microsoft products: Publisher, Microsoft Bob, Encarta, and Expedia. In 1994, she married Bill Gates, founder, chairman, and former chief software architect of Microsoft. Foundation Speakers: Victoria Hale, CEO, Institute for OneWorld Health Chris Hentschel, CEO, Medicines for Malaria Venture Lynn Marks, Senior Vice President, GlaxoSmithKline Wendy Taylor, Executive Director, BIO Ventures for Global Health The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., advances global health by developing new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health accomplishes this through an entrepreneurial business model in which its staff of experienced pharmaceutical scientists identifies promising drug leads and drives their development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3), U.S. corporation (www.oneworldhealth.org). |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion